Fig. 3From: Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malariaGraphical representation of Day 28 PCR-adjusted ACPR compared with ferroquine and artefenomel exposure. PK/PD efficacy population. Dotted lines represent median exposure in the PK/PD efficacy population for each drugBack to article page